51 completed, 5 recruiting, 4 active not recruiting, 4 enrolling by invitation. 69 Phase 3, 8 Phase 2.
Follow Angioedema: new trials by email Literature Review of Angioedema trials Research Report on Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Donidalorsen Treatment in Children With Hereditary Angioedema Donidalorsen - Hereditary Angioedema (HAE) | Phase 3 | Recruiting | Ionis Pharmaceuticals, Inc. | 20 | 2026-04-21 | 2026-11-02 |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) ADX-324 Dose Level 1, ADX-324 Dose Level 2 - Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2026-04-02 | 2026-09-04 |
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency Deucrictibant, Placebo - Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | Pharvaris Netherlands B.V. | 48 | 2025-10-16 | 2026-09-21 |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| A Study of Navenibart in Participants With Hereditary Angioedema navenibart, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Astria Therapeutics, Inc. | 157 | 2025-03-20 | 2026-06-30 |
| Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 170 | 2025-02-01 | 2026-09-22 |
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 3 | Active not recruiting | Intellia Therapeutics | 80 | 2025-01-15 | 2026-10-08 |
| Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema Conestat Alfa - ACE Inhibitor-Induced Angioedema | Phase 3 | Unknown | University of Cincinnati | 24 | 2024-12-01 | 2024-11-07 |
| Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE Deucrictibant, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Completed | Pharvaris Netherlands B.V. | 85 | 2024-12-01 | 2026-11-06 |
| Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 36 | 2024-08-01 | 2026-08-05 |
| Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks OCTA-C1-INH, Placebo - Acute Hereditary Angio Edema | Phase 3 | Recruiting | Octapharma | 124 | 2024-04-30 | 2026-11-13 |
| Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | Pharvaris Netherlands B.V. | 134 | 2024-02-26 | 2025-11-21 |
| CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema CSL312 - Hereditary Angioedema (HAE) | Phase 3 | Completed | CSL Behring | 22 | 2023-05-30 | 2026-06-02 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Berotralstat Treatment in Children With Hereditary Angioedema Berotralstat - Hereditary Angioedema, Pediatric | Phase 3 | Active not recruiting | BioCryst Pharmaceuticals | 29 | 2022-10-25 | 2026-02-25 |
| An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 145 | 2022-10-24 | 2026-06-05 |
| PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial KVD900 600 mg, Drug: KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | KalVista Pharmaceuticals, Ltd. | 11 | 2022-10-24 | 2026-06-08 |
| A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) Donidalorsen - Hereditary Angioedema | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 154 | 2022-07-13 | 2025-12-12 |
| A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) Lanadelumab - Hereditary Angioedema (HAE) | Phase 3 | Completed | Takeda | 20 | 2022-06-22 | 2024-12-13 |
Showing 20 of 69. Sign in to see all of them.
Angioedemas, Hereditary (60) · Hereditary Angioedema Types I and II (6) · Acquired angioedema (3) · Chronic Urticaria (2) · Genetic Diseases, Inborn (2) · Hereditary Angioedema Type III (2) · Edema (1) · Hypersensitivity (1) · Immune System Diseases (1) · Inflammation (1) · Multiple Organ Failure (1) · Pruritus (1) · Sepsis (1) · Urticaria (1)
Cardiovascular Diseases (69) · Hypersensitivity, Immediate (69) · Skin Diseases (69) · Skin Diseases, Vascular (69) · Skin and Connective Tissue Diseases (69) · Vascular Diseases (69) · Hypersensitivity (68) · Immune System Diseases (68) · Urticaria (68) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (60) · Hereditary Complement Deficiency Diseases (60) · Immunologic Deficiency Syndromes (60) · Primary Immunodeficiency Diseases (60) · Genetic Diseases, Inborn (58)
Complement C1 Inhibitor Protein (13) · lanadelumab (8) · Sodium Chloride (7) · icatibant (7) · berotralstat (5) · ecallantide (4) · sebetralstat (4) · conestat alfa (3) · donidalorsen (3) · IONIS-PKK-LRx (2) · Omalizumab (2) · avoralstat (2) · Fluid Therapy (1) · RNA, Small Interfering (1) · SERPING1 protein, human (1)
Shire (22) · BioCryst Pharmaceuticals (7) · CSL Behring (7) · Pharvaris Netherlands B.V. (5) · KalVista Pharmaceuticals, Ltd. (4) · Takeda (4) · Ionis Pharmaceuticals, Inc. (3) · Pharming Technologies B.V. (3) · ADARx Pharmaceuticals, Inc. (2) · Astria Therapeutics, Inc. (2) · Novartis Pharmaceuticals (2) · Prothya Biosolutions (2) · AO GENERIUM (1) · Intellia Therapeutics (1) · Johann Wolfgang Goethe University Hospital (1)
United States (46) · Canada (39) · Germany (36) · Spain (29) · Italy (27) · United Kingdom (26) · France (25) · Hungary (25) · Israel (25) · Poland (21) · Australia (20) · Japan (20) · Netherlands (20) · Bulgaria (17) · Romania (16)
Lauge Farnaes, MD (2) · M. M. Levi, Prof. Dr. (2) · Anurag Relan, MD (1) · Bruce Zuraw, MD (1) · Gentry Wilkerson, MD (1) · Henriette Farkas, MD (1) · Henriette Farkas, MD, PhD, DSc (1) · Isao Ohsawa (1) · Jan Nuijens, MD, PhD (1) · Jolanta Bernatoniene, MD (1) · Joseph A. Moellman, MD (1) · Luke P Leenen, MD, PhD (1)
PMID 36326435, PMID 20818886, PMID 23312695, PMID 23548529, PMID 23878046, PMID 24712435, PMID 36408587, PMID 42159953, PMID 20818888, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 28284978, PMID 36153561, PMID 37028510, PMID 40380356, PMID 40469312, PMID 40886933, PMID 42268494, PMID 17073887, PMID 19767078, PMID 20674826, PMID 20818887, PMID 21195947, PMID 21884533, PMID 21988742, PMID 22123383, PMID 22192966, PMID 22856636, PMID 22909164, PMID 23167682, PMID 23535096, PMID 24111645, PMID 24266596, PMID 24438203, PMID 24749847, PMID 25198193, PMID 25295804, PMID 26556097, PMID 27010957, PMID 28328347, PMID 28601641, PMID 28662509, PMID 29043014, PMID 30480729, PMID 30682573
2004 (2), 2015 (2), 2019 (2), 2008 (1), 2009 (1), 2014 (1), 2018 (1), 2023 (1), 2025 (1)